Amgen's KRAS Inhibitor AMG 510 Leans Toward Tumor-Dependent, Not Agnostic, Approach
Executive Summary
SVP Elliott Levy said the company hasn't ruled out a tumor-agnostic approach for AMG 510, but Phase I data for the first-in-class drug show a bigger effect in lung cancer – a 50% response rate, so far – than in colorectal cancer patients with a KRAS G12C mutation.
You may also be interested in...
US FDA Eyes Ways To Improve Conduct, Mitigate Bias In Open-Label Cancer Studies
At advisory committee review of confirmatory trial results for Amgen’s Lumakras, Oncology Center of Excellence’s Richard Pazdur cites need for a broader conversation within the clinical trial community, including educating patients and investigators about the importance of staying on study even when randomized to a comparator arm.
Merck Joins KRAS Stampede In Deal With Otsuka Affiliates
Merck & Co. is paying $50m up front to combine preclinical KRAS-target cancer compound pipelines with Astex and Taiho, both affiliates of Japan’s Otsuka. The two biotechs could realize up to $2.5bn in earnouts under the collaboration.
ESMO Preview: Five Key Oncology Battlegrounds To Watch
GSK looks to become a cancer contender once again, while Merck and Roche go toe-to-toe in TNBC.